Patents Assigned to Baker IDI Heart & Diabetes Institute Holdings Ltd.
  • Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
    Patent number: 10994010
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: May 4, 2021
    Assignees: UNIVERSITAETSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Antibodies against Mac-1
    Patent number: 10919967
    Abstract: The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which a) binds to Mac-1, b) specifically inhibits the interaction of CD40L with activated Mac-1 and c) does not induce integrin outside-in signaling.
    Type: Grant
    Filed: June 13, 2017
    Date of Patent: February 16, 2021
    Assignees: ALBERT-LUDWIGS-UNIVERSITÄTFREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis
    Patent number: 9808522
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: November 7, 2017
    Assignees: UNIVERSITATSKLINIKUM FREIBURG, BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD.
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • Polylysine dendrimer contrast agent
    Patent number: 9127130
    Abstract: The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogs, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: September 8, 2015
    Assignees: STARPHARMA PTY LTD., BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LTD
    Inventors: Guy Yeoman Krippner, Zemin Wu, Karlheinz Peter, Christoph Hagemeyer, David Owen
  • Temperature sensitive conjugate compositions
    Patent number: 9035028
    Abstract: This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: May 19, 2015
    Assignees: Emory University, Baker IDI Heart & Diabetes Institute Holdings Ltd.
    Inventors: Elliot L. Chaikof, Karlheinz Peter, Danijal Topcic, Carolyn A. Haller, Wookhyun Kim
  • Selective Targeting of the CD40L/Mac-1 Interaction by Small Peptide Inhibitors and its Use for the Treatment of Inflammation and Atherogenesis
    Publication number: 20140147445
    Abstract: The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.
    Type: Application
    Filed: August 17, 2011
    Publication date: May 29, 2014
    Applicants: BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LTD., UNIVERSITATSKLINIKUM FREIBURG
    Inventors: Andreas Zirlik, Dennis Wolf, Karlheinz Peter
  • TEMPERATURE SENSITIVE CONJUGATE COMPOSITIONS, AND USES RELATED THERETO
    Publication number: 20130034552
    Abstract: This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.
    Type: Application
    Filed: March 8, 2011
    Publication date: February 7, 2013
    Applicants: Baker IDI Heart & Diabetes Institute Holdings Ltd., Emory University
    Inventors: Elliot L. Chaikof, Karlheinz Peter, Danijal Topcic, Carolyn A. Haller, Wookhyun Kim